Senate Report: Drugmakers Raised Prices Despite Trump Deals
A new Senate report led by Senator Bernie Sanders reveals that sixteen major pharmaceutical companies have continued to raise prescription drug prices despite entering into agreements with the Trump administration aimed at lowering costs. The analysis indicates that all involved firms increased prices on 337 drugs since January 2025, including treatments for cancer and multiple sclerosis, with some annual costs rising by over $14,000. The report criticizes the White House’s TrumpRx platform for failing to provide meaningful savings and potentially steering patients toward more expensive options. In response, the White House dismissed the findings, arguing that list prices are irrelevant and citing Bureau of Labor Statistics data showing a decline in actual patient payments. Meanwhile, the report highlights that these companies launched 23 new drugs with an average price of $353,000 and saw a 66 percent increase in annual profits. This development underscores ongoing tensions between political efforts to control healthcare costs and pharmaceutical industry pricing strategies, affecting millions of Americans who struggle with medication affordability.
Wire timeline
Senate Report: Drugmakers Raised Prices Despite Trump Deals
A new Senate report led by Senator Bernie Sanders reveals that sixteen major pharmaceutical companies have continued to raise prescription drug prices despite entering into agreements with the Trump administration aimed at lowering costs. The analysis indicates that all involved firms increased prices on 337 drugs since January 2025, including treatments for cancer and multiple sclerosis, with some annual costs rising by over $14,000. The report criticizes the White House’s TrumpRx platform for failing to provide meaningful savings and potentially steering patients toward more expensive options. In response, the White House dismissed the findings, arguing that list prices are irrelevant and citing Bureau of Labor Statistics data showing a decline in actual patient payments. Meanwhile, the report highlights that these companies launched 23 new drugs with an average price of $353,000 and saw a 66 percent increase in annual profits. This development underscores ongoing tensions between political efforts to control healthcare costs and pharmaceutical industry pricing strategies, affecting millions of Americans who struggle with medication affordability.
The Independent World